The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced ...

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.Those who used GLP-1 receptor agonists exhibited ...

The majority of State Health Plan participants will become eligible in October for "an innovative no-cost surgical benefit" through a new partnership with a Dallas- based healthcare network. Treasurer ...

Online weight-loss company Noom said on Monday it would sell copies of Novo Nordisk's Wegovy at an introductory price of $119 for up to a quarter of the branded drug's standard dose, giving patients a ...

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

Janus Henderson Global Equity Income Fund returned 9.28% and the MSCI World IndexSM returned 11.47%. Read more here.